Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498806 | 0.89 | SIGMAR1 (0.75) | KDM4ESIGMAR1TAAR1AOC3SLC6A2 | |
| SCHEMBL19498789 | 0.85 | SIGMAR1 (1.00) | KDM4ESIGMAR1TAAR1AOC3ADRA2B | |
| SCHEMBL555308 | 0.82 | KDM4E (0.57) | KDM4ESIGMAR1TAAR1AOC3ADRA2B | |
| SCHEMBL8255372 | 0.82 | SIGMAR1 (0.69) | KDM4ESIGMAR1TAAR1AOC3ADRA2B | |
| SCHEMBL19954175 | 0.78 | SIGMAR1 (0.65) | KDM4ESIGMAR1TAAR1AOC3ADRA2B | |
| SCHEMBL27885210 | 0.78 | SIGMAR1 (0.65) | KDM4ESIGMAR1TAAR1AOC3 | |
| SCHEMBL7141888 | 0.76 | SIGMAR1 (0.61) | KDM4ESIGMAR1TAAR1AOC3 | |
| SCHEMBL11131474 | 0.75 | SIGMAR1 (0.66) | KDM4ESIGMAR1OPRK1KCNH2 | |
| SCHEMBL27416812 | 0.74 | TAAR1 (0.52) | KDM4ESIGMAR1TAAR1AOC3HTR2A | |
| SCHEMBL172915 | 0.74 | TAAR1 (0.52) | KDM4ESIGMAR1TAAR1AOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-09-17 | — | — | US | disclosed |
| US-20200237688-A1 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| US-10668030-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-10-26 | — | — | US | disclosed |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | KDM4E 1908/4885SIGMAR1 109/4885TAAR1 31/4885 |
| US-10668030-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | KDM4E 1908/4885SIGMAR1 109/4885TAAR1 31/4885 |
| US-20200237688-A1 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | SLC18A2, SLC6A2, SLC6A3 | KDM4E 1908/4885SIGMAR1 109/4885TAAR1 31/4885 |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | KDM4E 1908/4885SIGMAR1 109/4885TAAR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.